Unknown

Dataset Information

0

C3a receptor blockade protects podocytes from injury in diabetic nephropathy.


ABSTRACT: Renal activation of the complement system has been described in patients with diabetic nephropathy (DN), although its pathological relevance is still ill-defined. Here, we studied whether glomerular C3a, generated by uncontrolled complement activation, promotes podocyte damage, leading to proteinuria and renal injury in mice with type 2 diabetes. BTBR ob/ob mice exhibited podocyte loss, albuminuria, and glomerular injury accompanied by C3 deposits and increased C3a and C3a receptor (C3aR) levels. Decreased glomerular nephrin and ?-actinin4 expression, coupled with integrin-linked kinase induction, were also observed. Treatment of DN mice with a C3aR antagonist enhanced podocyte density and preserved their phenotype, limiting proteinuria and glomerular injury. Mechanistically, ultrastructural and functional mitochondrial alterations, accompanied by downregulation of antioxidant superoxide dismutase 2 (SOD2) and increased protein oxidation, occurred in podocytes and were normalized by C3aR blockade. In cultured podocytes, C3a induced cAMP-dependent mitochondrial fragmentation. Alterations of mitochondrial membrane potential, SOD2 expression, and energetic metabolism were also found in response to C3a. Notably, C3a-induced podocyte motility was inhibited by SS-31, a peptide with mitochondrial protective effects. These data indicate that C3a blockade represents a potentially novel therapeutic strategy in DN for preserving podocyte integrity through the maintenance of mitochondrial functions.

SUBMITTER: Morigi M 

PROVIDER: S-EPMC7141402 | BioStudies | 2020-01-01

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC7646996 | BioStudies
2019-01-01 | S-EPMC6536504 | BioStudies
2011-01-01 | S-EPMC3104745 | BioStudies
2015-01-01 | S-EPMC4407856 | BioStudies
1000-01-01 | S-EPMC5118481 | BioStudies
2019-01-01 | S-EPMC6586875 | BioStudies
1000-01-01 | S-EPMC3900538 | BioStudies
2014-01-01 | S-EPMC3973074 | BioStudies
1000-01-01 | S-EPMC3013527 | BioStudies
2020-01-01 | S-EPMC7326296 | BioStudies